Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 multiple-dose SOBI003 study in pediatric MPS IIIA
NL-OMON45765Phase 2Withdrawn
- Sponsor
- Recordati SpA
- Start
- Nov 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of SOBI-003 in mucopolysaccharidosis type III A, sponsored by Recordati SpA. Primary endpoints: Treatment-emergent adverse events and Serious adverse events. Planned start Nov 2018; status: withdrawn.
02
Drugs
SOBI-003
03
Conditions
mucopolysaccharidosis type III A
Beyond the preview
Go deeper on NL-OMON45765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45765.